Figure 1.

Impact of using beta-blockers on survival of patients across cancer types. Cancer-related mortality, estimated based on data from the FDA Adverse Event Reporting System. Bars indicate mortality rates for each cancer, bars to left indicate decreased survival on beta-blockers and bars to right show survival benefits on using beta-blocker (number of patients are included within parentheses). Mortality reduction over all cancer types is indicated by the dashed yellow line at 17% [15].